

**CORRECTION**

# Correction: Chronic clozapine treatment restrains via HDAC2 the performance of mGlu2 receptor agonism in a rodent model of antipsychotic activity

Mario de la Fuente Revenga<sup>1</sup>, Daisuke Ibi<sup>1,2,3</sup>, Travis Cuddy<sup>1</sup>, Rudy Toneatti<sup>1</sup>, Mitsumasa Kurita<sup>2,8</sup>, Maryum K. Ijaz<sup>1</sup>, Michael F. Miles<sup>4,5</sup>, Jennifer T. Wolstenholme<sup>4,5</sup> and Javier González-Maeso<sup>1,2,6,7</sup>

*Neuropsychopharmacology* (2019) 44:455–456; <https://doi.org/10.1038/s41386-018-0255-x>

Correction to: *Neuropsychopharmacology* <https://doi.org/10.1038/s41386-018-0143-4>; published online 07 July 2018.

Following the publication of this article, Figs. 3b and c were published incorrectly; the circle and square points above Chronic

clozapine were missing. The corrected Figure 3 is shown below. Also in sub-panel c of Fig. 4, 'Chronic clozapine' should read 'Chronic clozapine'.

The publishers wish to apologize for any inconvenience caused.

<sup>1</sup>Department of Physiology and Biophysics, Virginia Commonwealth University School of Medicine, Richmond, VA 23298, USA; <sup>2</sup>Department Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA; <sup>3</sup>Department of Chemical Pharmacology, Meijo University, Nagoya 468-8503, Japan; <sup>4</sup>Department of Pharmacology and Toxicology, Virginia Commonwealth University School of Medicine, Richmond, VA 23298, USA; <sup>5</sup>VCU Alcohol Research Center, Virginia Commonwealth University School of Medicine, Richmond, VA 23298, USA; <sup>6</sup>Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA and <sup>7</sup>Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA

Correspondence: Javier González-Maeso ([javier.maeso@vcuhealth.org](mailto:javier.maeso@vcuhealth.org))

<sup>8</sup>Present address: Dainippon Sumitomo Pharma Co., Ltd., Osaka 564-0053, Japan




Fig. 3